Another Top Pfizer Exec Resigns!

What is going on at Pfizer?

They seem to have a string of long-term executives leaving in a very short amount of time, maybe they cashed in on their stock options that no doubt surged to unprecedented levels over the course of this engineered ‘pandemic’.

Maybe they aren’t comfortable with what is going on, or maybe they simply fear the massive backlash that has already begun, but will no doubt take a turn for the worst for all those involved in the very near future.

Perhaps that is why they bolt from the scene when confronted by reporters. Iv’e seen folks run from the press or hide their faces before, but bolt? That unique honor belongs to one Pfizer executive.

Pfizer C.F.O. Frank D’Amelio made headlines today when his retirement was announced, and Pfizer is now reportedly searching for a new C.F.O. to take the seasoned executive’s place.

Here’s more on the story:

https://twitter.com/RieweStephanie/status/1461038559197020169

https://twitter.com/Alleninvest/status/1461031012687917069

The Wall Street Journal had more:

Mr. D’Amelio also serves as Pfizer’s executive vice president of global supply. In connection with Mr. D’Amelio’s planned retirement, Pfizer named Mike McDermott as chief global supply officer, effective Jan. 1. Mr. McDermott, who is currently president of global supply, will join Pfizer’s leadership team and report to Chief Executive Albert Bourla.

NATIONAL POLL: Will You Vote For Trump A THIRD Time?

The finance chief’s retirement comes as Pfizer ramps up production of its Covid-19 vaccine.

So after he got fat pushing a product that almost no one needs, and the Pfizer medical corporation reaped the harvest of its most profitable year, he is taking the money and running. https://t.co/Z0Sskbemaf#PfizerExposed #Pfizer #vaccine

— Vince Quill (@VinceQuill) November 17, 2021

https://twitter.com/pinkykisses/status/1460961693400453129

Business Wire quotes Pfizer C.E.O. Albert Bourla on D’Amelio’s departure:

“I want to thank Frank for his many years of service to Pfizer as CFO and for the impact he has had on the Company and the patients we serve,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

“Frank has driven a strategic vision for the Company’s financial success, and he leaves Pfizer in a strong position for future growth having been instrumental in our multi-year transformation to an industry leading, science-based biopharmaceutical company.”